Latest news about Zenith Health Care
Zenith Health Care
3.08
-0.02(-0.65%)
Company Performance:
View Company Insights1D-0.65%
1M-12.00%
6M-5.81%
1Y-20.62%
5Y-59.84%
More news about Zenith Health Care
11Apr 26
Zenith Healthcare Limited Declares Non-Applicability of Large Corporate Disclosure Requirements for FY26
Zenith Healthcare Limited submitted a declaration to BSE on April 11, 2026, confirming it does not qualify as a 'Large Corporate' under SEBI Circular SEBI/HO/DDHS/CIR/P/144 for FY26. The company reported nil outstanding borrowings as of March 31, 2026, and confirmed non-applicability of debt securities disclosure requirements. The declaration was authorized by Chairman Mahendra C. Raycha, Company Secretary Mihir S. Shah, and CFO Prashant Gupta.
11Apr 26
Zenith Healthcare Limited Submits RTA Declaration for Quarter Ended March 31, 2026
Zenith Healthcare Limited filed its quarterly RTA declaration under Regulation 74(5) of Depositories and Participants Regulations 2018 for Q4 FY26 ended March 31, 2026. The company submitted the mandatory compliance document to BSE on April 11, 2026, along with a certificate from Bigshare Services Private Limited confirming proper handling of dematerialization processes and compliance with regulatory requirements.
12Feb 26
Zenith Healthcare Reports Strong Q3FY26 Turnaround with ₹22.41 Lakh Net Profit
Zenith Healthcare Limited reported a strong financial turnaround in Q3FY26 with net profit of ₹22.41 lakh compared to a loss of ₹29.22 lakh in Q3FY25. Revenue from operations increased to ₹248.30 lakh, while the nine-month period showed net profit of ₹34.71 lakh against previous year's loss of ₹4.27 lakh. The company demonstrated improved operational efficiency with reduced material costs and positive earnings per share of ₹0.042.
11Nov 25
Zenith Healthcare Reports Mixed Q2 Results with Revenue Dip, Profit Growth for H1 FY2026
Zenith Healthcare Limited released its Q2 FY2026 results, showing a 9.6% quarter-on-quarter decline in revenue to ₹302.79 crore and a 9.5% drop in net profit to ₹21.88 crore. However, half-yearly results were more positive, with H1 FY2026 revenue increasing 14% year-over-year to ₹638.58 crore and net profit surging 70.9% to ₹39.34 crore. The company's balance sheet remains strong with total equity of ₹752.92 lakh against total assets of ₹1,072.03 lakh. The Board approved these results on November 11, 2025.
Industry Peers
Sun Pharmaceutical
Divis Laboratories
Torrent Pharmaceuticals
Cipla
Zydus Life Science
Lupin
Dr Reddys Laboratories
Mankind Pharma
Laurus Labs
Aurobindo Pharma
1,910.00
(+0.40%)
8,496.00
(-1.17%)
4,886.50
(-0.20%)
1,437.90
(+0.40%)
1,103.80
(-1.45%)
2,188.00
(-0.63%)
1,190.00
(+1.30%)
2,374.50
(-0.40%)
1,801.00
(-0.06%)
1,608.00
(-0.82%)
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
